Basic Science Emerging Topic Conference: The Intestinal Microbiome as an Approach to Liver Wellness

Participate in an exciting addition to Digestive Disease Week! This special day-and-a-half basic science course will arm you with some of the most advanced science you need to succeed. Titled: "Navigating the Intricacies of Microbiome’s Impact on Liver Health, and Pioneering Revolutionary Advances to Prevent Liver Disease" this DDW course is not to be missed!

When & Where

Date: Saturday, May 18, 8:00 am - Sunday, May 19, 11:30 am (EDT)
Location: Washington, DC
Continuing Education Credits: Continuing Medical Education (CME): 10.50 AMA PRA Category 1 Credits™ ABIM MOC points: 10.50 MOC points

logo for DDW 2024

 

Join AASLD for an enlightening session where experts delve into groundbreaking research at the intersection of microbiome science and liver health. Participants will explore the profound impact of alcohol on liver health and how the microbiome plays a pivotal role in treating alcohol-associated liver diseases.

By attending this program, attendees can expect to gain valuable knowledge and practical insights that will positively impact their research, clinical practice, and approach to liver health and disease. 

Key takeaways for attendees:

  • Comprehensive understanding of the microbiome’s impact on the liver.
  • Promising frontiers in liver disease treatment.
  • Translational insights into microbiome-based therapies.
  • Diversity, equity and inclusion (DEI) in hepatology.
  • Meaningful dialogue and idea exchange to foster collaborations and take home new perspectives.
  • Emerging research on virome, the intestinal-immune system, industrialization’s impact and much more.

Program Chairs

  • Cristina Llorente, PhD, MSs
  • Suthat Liangpunsakul, MD, MPH, AGAF, FAASLD

Location

Walter E Washington Convention Center
801 Allen Y. Lew Place NW
Washington, DC 20001

Registration

Registration is now open through DDW

Travel Note

US residents: Please review the Real ID Act regarding boarding federally regulated commercial aircrafts. Due to circumstances resulting from the COVID-19 pandemic, the Department of Homeland Security has extended the REAL ID enforcement deadline to May 3, 2023. Depending on your state of residence, you may need to provide a second form of identification at the airport.

Program Agenda

 

Session I: A New Era of Liver Health: Unraveling the Complexities of Alcohol-Associated Disease Through Microbiome and Therapeutic Discoveries

Moderators: Suthat Liangpunsakul, MD, MPH, AGAF, FAASLD (Indiana University School of Medicine) and Cristina Llorente (UC San Diego)

  • The Role of the Microbiome and Virome in Liver Pathophysiology
    Cynthia L. Hsu, MD (UC San Diego)
  • Microbiota and Liver Health: Insights and Advances in Diagnosis and Treatment
    Jasmohan Bajaj, MD, FAASLD (Virginia Commonwealth University and Central Virginia Veterans Healthcare System)
  • Uncovering the Role of Gut-Liver Axis and Neutrophil Extracellular Traps in Alcohol-Associated Liver Disease
    Gyongyi Szabo, MD, PhD, FAASLD, AGAF, FACP (Harvard Medical School)
  • The Protective Role of Batf3-Dependent Conventional Type 1 Dendritic Cells in Alcoholic Liver Disease: Exploring the Akkermansia Muciniphila Connection
    Liuyi Hao, PhD (Center for Translational Biomedical Research)

Session II: Unlocking the Secrets of the Gut Microbiome: Implications for Metabolic Syndrome and Metabolic Dysfunction-Associated Steatotic Liver Disease

Moderators: Cynthia L. Hsu, MD and Jasmohan Bajaj, MD, FAASLD

  • Recent Advances in Prediction of Metabolic Dysfunction-Associated Steatotic Liver Disease and Cirrhosis: Insights from the Gut Microbiome 
    Rohit Loomba, MD, MHSc, FAASLD (UC San Diego)
  • Advancing Mass Spectrometry Insights in Metabolic Disorders and Liver Diseases
  • The Role of Western Diet and Gut Microbiota in Metabolic Dysfunction-Associated Steatohepatitis (MASH): Insights into Mediators and Therapeutic Targets
    Guangfu Li, DVM, MSc, PhD (University of Missouri)
  • The Gut Microbiota Rhythms in Metabolic Homeostasis and Metabolic Dysfunction-Associated Steatohepatitis (MASH): Insights from Machine Learning Analyses
    Vanessa A. Leone, PhD (University of Chicago)

Session III: Exploring the Revolutionary Potential of Gut-Liver Axis Research in Health and Disease

Moderators: Rohit Loomba, MD, MHSc, FAASLD (UC San Diego) and Vanessa A. Leone

  • Exploring Gut Microbiota Translocation to Liver and Spleen: Unveiling Commensal Bacteria and Systemic Immune Responses in Inflammatory Diseases
    Yasmine Belkaid, PhD (National Institute of Allergy and Infectious Diseases)
  • Microbial Ethanol in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Unraveling the Role of Gut Microbiome in Disease Progression
    Max Nieuwdorp, PROFDR (Amsterdam University Medical Centers)
  • Unraveling the Role of Intestinal Osteopontin in Host-Microbiome Interactions and its Implications for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
    Hui Han (University of Illinois College of Medicine, UIC)
  • Deciphering BilR: A Gut Microbial Enzyme Orchestrating Bilirubin Reduction to Urobilinogen and Its Impact on Human Health
    Xiaofang Jiang, (National Library of Medicine, National Institutes of Health, Bethesda, MD, USA)

Session IV: New Insights on Combating Liver Disease: Cutting-Edge Research on Bacteriophages, Mycobiome, and Microbiome

Moderators: Max Nieuwdorp, PROFDR (Amsterdam University Medical Centers) and Marlies Meisel, PhD (University of Pittsburgh School of Medicine)

  • Exploring the Interplay of Microbiome, Mycobiome, and Bacteriophages in Liver Diseases 
    Bernd Schnabl, MD, FAASLD (UC San Diego)
  • Bridging the Gut-Liver Axis: Gut Microbiome's Influence on Hepatocellular Carcinoma (HCC) Immune Microenvironment
    Amany Zekry (UNSW Microbiome Research Centre, St George and Sutherland Clinical School, UNSW Sydney, NSW, Australia
  • Decoding the Microbiome: Insights into Liver Disease, Metabolic Disorders and Inflammatory Bowel Disease
    Eren Elinav (Weizmann Institute of Science, Israel)
  • Evaluating the Role of Evolutionary Adaptation in Commensal Pathogenicity: Insights into Bacterial Translocation to the Liver and Immune-Mediated Diseases
    Noah W. Palm, PhD (Yale University School of Medicine)

Session V: Exploring the Microbiome Interactions with the Enteric Nervous System and the Immune System: Insights Into Liver Disease, Infectious Diseases, Diabetes and Pioneering Clinical Trials

Moderators: Amany Zekry (UNSW Microbiome Research Centreand Eren Elinav (Weizmann Institute of Science, Israel)

  • Deciphering Microbial Induced Fibrosis: Unraveling the Impact of the Gut Microbiota on Liver Fibrosis and Hepatocellular Carcinoma (HCC)
    Marlies Meisel, PhD (University of Pittsburgh School of Medicine)
  • Microbiota-Derived D-Lactate Enhances Neutrophil Recruitment to the Liver During Systemic Infections: Implications for Immune Defense
    Amanda Z. Zucoloto (University of Calgary)
  • Translating Microbiome Discoveries: Pioneering Clinical Trials in Gastrointestinal Health
    Sahil Kanna (Mayo Clinic) 
  • Unraveling the Role of Aberrant Serine Homeostasis in Diabetes: Implications for Multiple Organ Damage Including Liver, Kidneys, and Peripheral Nerves
    Michał Handzlik (The Salk Institute for Biological Studies) and Christian M. Metallo, PhD (The Salk Institute for Biological Studies)

Session VI: Meet the Speakers

The format of the discussion will involve a designated leader who will introduce a topic related to the microbiome. This introduction will be limited to a 5-minute time frame. Following the introduction, experts in the field will engage in a constructive dialogue to explore and discuss the importance of the microbiome. The aim of this format is to create an environment where experts can share their knowledge and insights in a collaborative manner, ultimately leading to a deeper understanding of the microbiome and its role in health and disease.

  • Microbiome’s Role in Alcohol-Associated Liver Disease: Insights from Leading Experts
    Leader: Cynthia L. Hsu, MD
    Discussion Team: Jasmohan Bajaj, MD, FAASLD, Gyongyi Szabo, MD, PhD,FAASLD, AGAF, FACP, and Liuyi Hao, PhD
  • Exploring the Role of the Microbiome in Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Syndrome: Perspectives from Renowned Experts
    Leader: Vanessa A. Leon
    Discussion Team: Guangfu Li, DVM, MSc, PhD, Ipsita Mohanty, and Rohit Loomba, MD, MHSc, FAASLD
  • Revolutionizing Our Understanding of Liver Health: Insights from Experts in Microbiome Research
    Leader: Yasmine Belkaid 
    Discussion Team: Bernd Schnabl, PhD, Eren Elinav, and Yasmine Belkaid 
  • Exploring Microbiome With Multifaceted Experts: Liver Disease, Infectious Diseases, Metabolic Disorders, and Diabetes and Clinical Trials
    Leader: Marlies Meisel, PhD
    Discussion Team: Sahil Kanna, PhD, Amanda Z. Zucoloto,and Max Nieuwdorp, PROFDR

Registration Pricing

General

Regular Rate $190

Continuing Education

Continuing Medical Education (CME)

Accreditation Statement: The American Association for the Study of Liver Diseases (AASLD) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation Statement: AASLD designates this enduring activity for a maximum of 14.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine Maintenance of Certification (MOC) 

Successful completion of this CME activity, which includes participation in the evaluation components, enables the participant to earn up to 10.50 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

CME Credits

Physicians seeking AMA PRA Category 1 CME Credits™ for this live activity must complete the meeting evaluation for DDW 2024. A link to the CME evaluation will be emailed to attendees after the course.

ABIM MOC Points

Physicians seeking ABIM MOC points must complete the CME and MOC evaluations for DDW 2024. Requests for MOC points after this date will not be honored. The MOC evaluation will be available online along with the CME evaluation.